TVRD

SEC source: 0001209191-18-033520 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Sr VP-Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,000

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2017.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 - $15.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.

SEC source: 0001209191-18-019398 · doc4.xml · derivative · entry 1

CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 187,500

Underlying: Common Stock · 187,500 shares

Expires 2028-03-09

F1 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on April 9, 2018, in each case subject to the Reporting Person's Continuous service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date.

SEC source: 0001209191-18-019405 · doc4.xml · derivative · entry 1

Stauffer Joseph William · CIK 0001466459 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,750

Underlying: Common Stock · 57,750 shares

Expires 2028-03-09

F1 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on April 9, 2018, in each case subject to the Reporting Person's Continuous service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date.

SEC source: 0001209191-18-019407 · doc4.xml · derivative · entry 1

Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,500

Underlying: Common Stock · 46,500 shares

Expires 2028-03-09

F1 · derivative.exercise_date: The shares shall vest in a series of 48 successive equal monthly installments beginning on April 9, 2018, in each case subject to the Reporting Person's Continuous service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date.

SEC source: 0001209191-18-019400 · doc4.xml · derivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Sr VP-Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,750

Underlying: Common Stock · 57,750 shares

Expires 2028-03-09

F1 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on April 9, 2018, in each case subject to the Reporting Person's Continuous service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date.

SEC source: 0001209191-18-012008 · doc4.xml · nonDerivative · entry 1

CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,071,392

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 15, 2017.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 - $15.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001209191-18-011372 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Sr VP-Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 119,000

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2017.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 - $15.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.

SEC source: 0001209191-18-005678 · doc4.xml · derivative · entry 3

CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 191,000

Underlying: Common Stock · 3,000 shares

Expires 2026-03-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on April 8, 2017, in each case subject to the Reporting Person's Continuous service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date.

SEC source: 0001209191-18-005678 · doc4.xml · nonDerivative · entry 2

CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,076,792

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-18-005678 · doc4.xml · nonDerivative · entry 1

CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,073,792

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 15, 2017.

SEC source: 0001209191-18-005679 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Sr VP-Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 122,000

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2017.

SEC source: 0001209191-17-059985 · doc4.xml · derivative · entry 2

Menzaghi Frederique Ph.D. · CIK 0001597152 · Sr VP-Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,000 shares

Expires 2017-11-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001209191-17-059985 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Sr VP-Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 137,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-17-059277 · doc4.xml · derivative · entry 3

CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,000 shares

Expires 2017-11-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001209191-17-059277 · doc4.xml · nonDerivative · entry 2

CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,086,292

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-17-059277 · doc4.xml · nonDerivative · entry 1

CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,066,292

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 15, 2017.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.55 - $12.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001209191-17-050188 · doc4.xml · derivative · entry 1

Mohindru Mani · CIK 0001664708 · CFO & Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 385,000

Underlying: Common Stock · 385,000 shares

Expires 2027-08-15

F1 · derivative.exercise_date: One-fourth (1/4th) of the shares shall vest and become exercisable on August 15, 2018; the balance of the shares shall vest and become exercisable in a series of 36 successive equal monthly installments measured from August 15, 2018, subject to the reporting person's continuous service with the issuer as of each such date.

SEC source: 0001209191-17-048459 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · VP-Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 117,000

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2017.

SEC source: 0001209191-17-046598 · doc4.xml · derivative · entry 2

Schoell Josef · CIK 0001597186 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,000 shares

Expires 2018-08-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001209191-17-046598 · doc4.xml · nonDerivative · entry 1

Schoell Josef · CIK 0001597186 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-17-045567 · doc4.xml · derivative · entry 3

CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 10,000 shares

Expires 2017-11-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001209191-17-045567 · doc4.xml · nonDerivative · entry 2

CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,082,292

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 15, 2017.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 - $15.135, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001209191-17-045567 · doc4.xml · nonDerivative · entry 1

CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,107,292

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-17-045566 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · VP-Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,000

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2017.

SEC source: 0001209191-17-042886 · doc4.xml · nonDerivative · entry 2

Slagel Dean · CIK 0001597359 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Esperante Holding NV

Disclosed balance after: 1,064,338

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Esperante Holding NV on June 14, 2017 (See Footnote 3 herein).

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.50 - $27.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.

F3 · ownership.nature: These shares are owned by Esperante Holding NV. The Reporting Person is a director of the Issuer and the Managing Director of Esperante BV, a wholly-owned subsidiary of Esperante Holding NV. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-17-042886 · doc4.xml · nonDerivative · entry 1

Slagel Dean · CIK 0001597359 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Esperante Holding NV

Disclosed balance after: 1,085,200

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Esperante Holding NV on June 14, 2017 (See Footnote 3 herein).

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.47 - $26.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

F3 · ownership.nature: These shares are owned by Esperante Holding NV. The Reporting Person is a director of the Issuer and the Managing Director of Esperante BV, a wholly-owned subsidiary of Esperante Holding NV. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-17-041753 · doc4.xml · derivative · entry 1

VOGELBAUM MARTIN · CIK 0001237624 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2027-06-21

F1 · derivative.exercise_date: This option was granted to the reporting person pursuant to the issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on June 21, 2018, subject to the reporting person's continued service as a director through such date.

SEC source: 0001209191-17-041747 · doc4.xml · derivative · entry 1

BAINS HARRISON M JR · CIK 0001202282 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2027-06-21

F1 · derivative.exercise_date: This option was granted to the reporting person pursuant to the issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on June 21, 2018, subject to the reporting person's continued service as a director through such date.

SEC source: 0001209191-17-041748 · doc4.xml · derivative · entry 1

Ives Jeffrey L. · CIK 0001614096 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2027-06-21

F1 · derivative.exercise_date: This option was granted to the reporting person pursuant to the issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on June 21, 2018, subject to the reporting person's continued service as a director through such date.

SEC source: 0001209191-17-041750 · doc4.xml · derivative · entry 1

Slagel Dean · CIK 0001597359 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2027-06-21

F1 · derivative.exercise_date: This option was granted to the reporting person pursuant to the issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on June 21, 2018, subject to the reporting person's continued service as a director through such date.

SEC source: 0001179110-17-005327 · edgar.xml · nonDerivative · entry 1

RHO Ventures VI LP · CIK 0001419636 · 10% owner

RMV VI, L.L.C. · CIK 0001478944 · 10% owner

Rho Capital Partners LLC · CIK 0001325385 · 10% owner

LESCHLY MARK · CIK 0001120545 · 10% owner

KAIROUZ HABIB · CIK 0001082907 · 10% owner

RUCH JOSHUA · CIK 0000943431 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,568,057

F1 · ownership.nature: These securities are owned directly by Rho Ventures VI, L.P. ("RV VI"). RMV VI, L.L.C. ("RMV") is the general partner of RV VI and Rho Capital Partners LLC ("RCP") is the managing member of RMV. Mark Leschly, Habib Kairouz and Joshua Ruch are managing members of RCP and exercise shared voting and investment power with respect to the shares owned by RV VI. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his or its respective pecuniary interest therein.

SEC source: 0001209191-17-019917 · doc4.xml · derivative · entry 1

CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 225,000

Underlying: Common Stock · 225,000 shares

Expires 2027-03-08

F1 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on April 8, 2017, in each case subject to the Reporting Person's Continuous service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date.

SEC source: 0001209191-17-019913 · doc4.xml · derivative · entry 1

Stauffer Joseph William · CIK 0001466459 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2027-03-08

F1 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on April 8, 2017, in each case subject to the Reporting Person's Continuous service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date.

SEC source: 0001209191-17-019916 · doc4.xml · derivative · entry 1

Lewis Michael E · CIK 0001297065 · Chief Scientific Advisor

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2027-03-08

F1 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on April 8, 2017, in each case subject to the reporting person's Continuous Service (as defined in the 2014 Equity Incentive Plan) as of each such date.

SEC source: 0001209191-17-019915 · doc4.xml · derivative · entry 1

Schoell Josef · CIK 0001597186 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2027-03-08

F1 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on April 8, 2017, in each case subject to the Reporting Person's Continuous service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date.

SEC source: 0001209191-17-019914 · doc4.xml · derivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · VP-Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2027-03-08

F1 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on April 8, 2017, in each case subject to the Reporting Person's Continuous service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date.